Trial Profile
Long Term Follow Up for Patients Who Have Received Allogeneic Stem Cell Transplantation of NiCord/CordIn, Umbilical Cord Blood-derived Ex Vivo Expanded Stem and Progenitor Cells
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Aug 2023
Price :
$35
*
At a glance
- Drugs Omidubicel (Primary)
- Indications Haematological malignancies; Sickle cell anaemia; Thalassaemia
- Focus Therapeutic Use
- Sponsors Gamida-Cell
- 27 Jul 2023 Status changed from active, no longer recruiting to completed.
- 08 Jun 2022 Planned End Date changed from 1 Jun 2022 to 1 Jul 2023.
- 08 Jun 2022 Planned primary completion date changed from 1 Jun 2022 to 1 Jul 2023.